Press Releases Keyword Search Year None20242023202220212020 Apr 22, 2024 CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting Apr 03, 2024 CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference Apr 01, 2024 CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting Mar 13, 2024 CRISPR Therapeutics Proposes New Appointment to the Board of Directors Feb 21, 2024 CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results Feb 15, 2024 CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit Feb 13, 2024 CRISPR Therapeutics Announces $280 Million Registered Direct Offering Feb 13, 2024 European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) Jan 16, 2024 CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia Jan 08, 2024 CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook Jan 03, 2024 CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference